This report provides an
overview of the pipeline landscape for diabetes and associated metabolic
conditions. It provides comprehensive information on the therapeutics under
development and key players involved in therapeutic development for type I
diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features
dormant and discontinued products.
Diabetes refers to a group of
metabolic diseases that result from defects in insulin secretion, insulin
action or both of these. Type I diabetes is an autoimmune disease in which the
pancreas stops producing insulin, a hormone that enables people to get energy
from food. It occurs when the body's immune system attacks and destroys the
insulin-producing cells in the pancreas, called beta cells. There are 263
products in development for this indication.
Type 2 diabetes, however,
results from a combination of resistance to insulin action and an inadequate
compensatory insulin secretory response. Type 2 diabetes is more closely
related to lifestyle choices such as diet and exercise habits than type I
diabetes, with the majority of patients being overweight or obese. There are
574 products in development for this indication.
Hyperinsulinemia is a condition
in which there are excess levels of insulin circulating in the blood relative
to the level of glucose. Insulin resistance is the primary cause of
hyperinsulinemia. There are 10 products in development for this indication.
Hyperglycemia is a condition
that occurs when blood glucose levels get too high. Several factors can
contribute to hyperglycemia, including food and physical activity choices,
illness, non-diabetes medications, or not taking enough glucose-lowering
medication. There are seven products in development for this indication.
Molecular targets acted on by
products in development for diabetes and associated metabolic conditions
include the insulin receptor, glucagon-like peptide 1 (GLP-1) receptor,
glucagon receptor and glucokinase. Companies operating in this pipeline space
include Novo Nordisk, Eli Lilly and Zealand Pharma
The report also covers the
following topics:-
Which companies are the most
active within each pipeline?
- Which pharmaceutical
approaches are the most prominent at each stage of the pipeline and within each
indication?
- To what extent do
universities and institutions play a role within this pipeline, compared to
pharmaceutical companies?
- What are the most important
R&D milestones and data publications to have happened in this disease area?
- Understand the overall
pipeline, with an at-a-glance overview of all products in therapeutic
development for each indication
- Assess the products in
development in granular detail, with an up-to-date overview of each individual
pipeline program in each indication and a comprehensive picture of recent
updates and milestones for each
- Analyze the companies,
institutions and universities currently operating in the pipeline and the
products being fielded by each of these
- Understand the composition of
the pipeline in terms of molecule type, molecular target, mechanism of action
and route of administration
To know more, click on the link
below:
Contact Us:
Ken Research
Ankur Gupta,
Head Marketing & Communications
+91-9015378249
